Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.43 |
| ▸ | BCL2 | P10415 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090165 | 0.85 | PPARG (0.42) | MDM2MCL1BCL2PPARGEGLN1 | |
| SCHEMBL4095158 | 0.77 | ADRB3 (0.38) | PPARGMAPTEGLN1HRH3 | |
| SCHEMBL4094387 | 0.76 | PTGES (0.47) | MDM2MCL1BCL2PPARGMAPT | |
| SCHEMBL4095879 | 0.73 | PPARG (0.43) | MDM2MCL1BCL2PPARGPTGER4 | |
| SCHEMBL333839 | 0.72 | PPARG (0.47) | MDM2MCL1BCL2PPARGKDM4E | |
| SCHEMBL4701667 | 0.72 | PTGES (0.46) | MDM2MCL1BCL2PPARGMAPT | |
| SCHEMBL4224601 | 0.70 | PTGES (0.58) | MDM2MCL1BCL2PPARGKDM4E | |
| SCHEMBL4095050 | 0.70 | PTGES (0.48) | MDM2MCL1BCL2PPARGGCK | |
| SCHEMBL333958 | 0.70 | KDM4E (0.42) | PPARGMAPTKDM4EMEN1HTT | |
| SCHEMBL333957 | 0.68 | MAPT (0.42) | PPARGMAPTKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | MDM2 2780/4885MCL1 1709/4885BCL2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.